Eli Lilly has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 release. Alchemab will receive an undisclosed upfront payment and can also earn payments based on hitting milestones, as well as royalties. Source: Fierce Biotech 9/1/2025